Market News

Alzheimer’s Stock Prothena (NASDAQ:PRTA) Takes Wings

Shares of clinical-stage company Prothena (NASDAQ:PRTA) are soaring today as Biogen’s (NASDAQ:BIIB) promising results for lecanemab put the spotlight on Alzheimer’s names.

Prothena has expertise in protein dysregulation and a pipeline focused on neurodegenerative and rare peripheral amyloid diseases including Alzheimer’s and Parkinson’s disease.

Is PRTA a Good Stock to Buy?

Overall the Street has a Strong Buy consensus rating on PRTA stock alongside an average price target of $69.60 which indicates a 27.36% potential upside.

That’s after a nearly 85% rise in Prothena stock over the past five days.

Read full Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More